SEC Tracker
Get the app

Immunic IMUX

Immunic FY 2021: net loss $92.9M; diluted EPS −$3.93

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Immunic reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$92.9MAgainst −$44.0M in FY 202010-K income statement, on EDGAR
  2. Diluted EPS−$3.93Against −$2.81 in FY 202010-K income statement, on EDGAR
  3. Cash and cash equivalents$86.9M−32% from $127.5M in FY 202010-K balance sheet, on EDGAR
  4. Cash from operations−$83.2MAgainst −$46.1M in FY 202010-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Immunic files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Coherus Oncology CHRS public float $82M, Jun 30, 2025
  2. Elicio Therapeutics ELTX public float $82M, Jun 30, 2025
  3. Entera Bio ENTX public float $85M, Jun 30, 2025
  4. Anixa Biosciences ANIX public float $85M, Apr 30, 2025, over 18 months old
  5. Filana Therapeutics FLNA public float $87M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.